B. Vanovermeire et al., ASPIRIN VERSUS INDOMETHACIN TREATMENT OF PATENT DUCTUS-ARTERIOSUS IN PRETERM INFANTS WITH RESPIRATORY-DISTRESS SYNDROME, Pediatric research, 38(6), 1995, pp. 886-891
Indomethacin (Indo) is commonly used for treatment of patent ductus ar
teriosus (PDA) but has renal failure as a main side effect. Aspirin (A
SA) is an alternative, but there are no controlled trials on its effic
acy. We randomly assigned 75 premature infants suffering from respirat
ory distress syndrome (RDS) (mean gestational age: 29.6 +/- 2.5 wk, me
an birth weight: 1295 +/- 464 g) (+/-SD) and on artificial ventilation
at the start of the study (mean: 3.4 d of life), to either Indo (3 x
0.2 mg/kg/12 h) or ASA (4 X 15 mg/kg/6 h). PDA and degree of shunting
were evaluated by echocardio-Doppler; side effects were carefully reco
rded. PDA closed in 35/38 patients from the Indo group (92%) and in 16
/37 patients from the ASA group (43%) (p < 0.0001). Nineteen patients
needed further treatment with Indo or surgery (17 in the ASA group and
2 in the Indo group). The only side effect observed was a decrease of
uresis in the Indo group during 4 d post treatment (p < 0.01). Closin
g of PDA was positively correlated with gestational age, but not with
time of starting Indo/ASA or grade of shunting. We conclude that ASA i
s not as effective in closing PDA as Indo, but has no adverse effect o
n uresis.